Morgan Stanley Maintains Equal-Weight on IGM Biosciences, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Lapides has maintained an Equal-Weight rating on IGM Biosciences (NASDAQ:IGMS) but reduced the price target from $15 to $8.
November 15, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley analyst Michael Lapides maintained an Equal-Weight rating on IGM Biosciences but lowered the price target from $15 to $8.
The reduction in price target by Morgan Stanley is likely to be viewed negatively by investors, as it suggests a lower expected future stock price. This could lead to a decrease in investor confidence and a potential short-term decline in the stock price of IGM Biosciences.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100